[Ip-health] Spicy IP: Mainstreaming delinkage

Thiru Balasubramaniam thiru at keionline.org
Fri Jun 27 04:53:52 PDT 2014


http://spicyip.com/2014/06/mainstreaming-delinkage.html

Mainstreaming delinkage
by Swaraj Paul BarooahJune 27, 2014
<http://spicyip.com/2014/06/mainstreaming-delinkage.html>

*At the 67th World Health Assembly*

Last month saw the occurrence of a development
<http://keionline.org/node/2015> which, even if small and under-reported, I
would consider to be of significant importance – when the 67th World Health
Assembly (WHA) announced a decision to give the World Health Organization
(WHO) Secretariat a mandate to create a pool fund that will allow the price
of a drug to be delinked from the R&D costs involved in creating that drug.
Though the fund is to be administered by the “Special Programme for
Research and Training in Tropical Diseases”, the WHA included a statement
recognizing that the fund was not to be limited only to “Type III” (i.e.,
tropical diseases), meaning it was to be made available other types of
diseases as well, including non-communicable diseases like cancerous
diseases. The decision is available here
<http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_BCONF2Rev1-en.pdf>.

In order to understand why a movement towards delinkage is important, as
several scholars have already pointed out, one only needs to look at the
effects of ‘drug price – R&D cost’ linkage. Essentially, it means that drug
innovation can be rewarded based on the usefulness of the drug, rather than
the pockets of the patient.

As drugs are expensive and risky to develop,  there is little incentive for
pharmaceutical companies to invest much in drug research but rather to
invest in ensuring sales are made. And thus we have the problem of
‘evergreening’, wherein pharmaceutical companies are incentivized into
trying to get successive patents on minor variations of a drug, so as to
extend their monopoly period. Similarly, there is little incentive to
developing treatments for diseases that predominantly affect the poor.

That’s also why, for example, despite the stark warnings that scientists
have been giving regarding the onset of a ‘post-antibiotic era
<http://www.nature.com/news/who-warns-against-post-antibiotic-era-1.15135>‘
(where our current antibiotics are rendered redundant due to resistant,
turning simple cuts, bruises and infections into potentially deadly
conditions) the drug pipeline seems to be empty of new lines of antibiotics
<http://motherboard.vice.com/read/theres-no-financial-incentive-to-make-the-antibiotics-we-need>.
Speaking of which…

*Longitude Prize*

On 25th June, the Longitude Prize 2014 (named after the prize instituted by
theBritish government in 1714
<https://en.wikipedia.org/wiki/Longitude_prize>) announced that their vote
count had come in, and the public had voted for their £10 million prize to
go towards solving this antibiotics crisis. The prize, which asks the
public to vote on which problem’s solution they think is the most in need
of a prize stimulation, puts forward global challenges under 6 broad
headings – energy, environment, global development, technology and
robotics, democratizing access to communications, and health and wellbeing.
The prize is open to anyone – from amateur scientists to professional labs
– for a period of 5 years. You can see more about how the prize works here
<http://www.longitudeprize.org/challenge/antibiotics>.

Just like the R&D fund mentioned above, a prize system also delinks R&D
costs from the ability of patients to pay for a treatment. With more prizes
like this coming to the fore, as well as mechanisms like the R&D fund
gaining more ground, it looks like there is some badly needed recognition
of the requirement to delink when it comes to public goods like public
health!



More information about the Ip-health mailing list